Regulatory – Page 21 – Alligator Bioscience

2017-09-21

Regulatory

Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017

Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2017-09-13

Regulatory

Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...

2017-08-23

Regulatory

“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...

2017-08-17

Regulatory

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden – August ...

2017-07-21

Regulatory

Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...

2017-06-12

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing antibody-based pharmaceuticals for canc ...

2017-05-04

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today presented new pre-clinical data on the CD40 agonistic immuno-oncology ...

2017-05-02

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017. “In the first quarte ...

2017-03-31

Regulatory

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the number of shares and votes in Alligator Bios ...